Eiger files for bank­rupt­cy and will wind down op­er­a­tions af­ter years of set­backs

Eiger Bio­Phar­ma­ceu­ti­cals said Mon­day morn­ing that it filed for Chap­ter 11 pro­tec­tion in the Unit­ed States Bank­rupt­cy Court for the North­ern Dis­trict of Texas.

The Pa­lo Al­to, CA-based biotech al­so said Sen­tynl Ther­a­peu­tics has inked a “stalk­ing horse” agree­ment for its ap­proved drug Zok­in­vy. If the court al­lows it, Sen­tynl could pay up to $26 mil­lion for the treat­ment. The drug was ap­proved in 2020 for Hutchin­son-Gil­ford prog­e­ria syn­drome, an ul­tra-rare dis­ease in which chil­dren age pre­ma­ture­ly and have a short life ex­pectan­cy of about 14 years.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.